Key point: According to a Phase III trial of the once-daily, investigational immunomodulatory laquinimod, this agent significantly reduced annualized relapse rate, risk of confirmed disability progression, and progression of brain atrophy, and was well-tolerated with a placebo-like adverse event profile.
.
****************************************************************
Know somebody affected by Multiple Sclerosis?
Ask them to remain CURRENT with Multiple Sclerosis news & information
when registered at the MS Views and News website
.Weekly e-Newsletter now reaching (87) Countries. .
***************************************************************************************
Help STUART to Educate: Please donate
– all contributions are tax deductible –
We are a 501c3 – Not for Profit Charity
.
“Providing You with ‘MS Views and News’, is what we do“
***************************************************************************************
.
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews